Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Complete Title: Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Trial Phase: N/A
Investigator: Erin Crotty
The DAY101-EAP is a multicenter, open-label, expanded access treatment protocol designed to provide access to tovorafenib (DAY101) for eligible patients.
Keywords:
- Glioma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
N/A
Erin Crotty
RG1123324
NCT05760586
Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Glioma